aVaxMed Limited is a biotech based in Oxfordshire, United Kingdom, that has developed a novel needle-free solid-dose vaccine delivery technology. Their vision is a world where access to vaccines is universal, and population health is not impacted by preventable disease. Their mission is to transform the vaccine landscape by removing barriers to better vaccine uptake, such as cold chain logistics and needles and syringes. The technology consists of two key elements, the solid dose vaccine (SDV) and a needle-free pen administration system. The SDV contains the vaccine, formulated with stabilisers and structural agents to create a robust and thermally stable vaccine dose. This dose is then pre-loaded into a disposable cassette that is attached to a reusable spring-powered injector pen that rapidly delivers the dose subcutaneously with minimal sensation. aVaxMed solid-dose vaccine technology addresses many of the problems that lead to vaccine wastage and suboptimal vaccine uptake and...